Wegovy, Ozempic costs fell within the first quarter
LONDON, Could 2 (Reuters) – Novo Nordisk has seen the worth of its massively common weight-loss drug Wegovy and diabetes drug Ozempic fall in america as volumes and competitors have elevated, a senior government mentioned on Thursday. Wegovy costs in america have been “barely down” within the first quarter and Novo expects additional decreases via the remainder of 2024, Chief Monetary Officer Karsten Munk Knudsen mentioned on a
Read More